Performance Evaluation of ANI in Patients Under General Anesthesia With Remimazolam
Performance Evaluation of Analgesia Nociception Index (ANI) in Patients Under General Anaesthesia With Remimazolam: a Prospective Observational Study
Catholic Kwandong University
30 participants
Apr 23, 2024
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine whether Analgesia Nociception Index (ANI) can effectively reduce the dose of opioid in patients who underwent general anesthesia using remimazolam.
Eligibility
Inclusion Criteria5
- Patients
- aged 20-79 years under general anaesthesia with remimazolam
- scheduled to undergo robotic surgery
- in American Society of Anesthesiologists physical class 1, 2 or 3
- voluntarily agree in writing to participate in this clinical study
Exclusion Criteria5
- Conditions affecting the autonomic nervous system
- other conditions or disease that may cause acute or chronic pain
- the NRS before induction of anesthesia is 1 or over
- When taking medications that may affect the autonomic nervous system
- In other cases where the investigator deems the subject unsuitable for this trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam. During this study, remimazolam infusion rate is determined by the pharmacopoeia. Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model. ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06432894